Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources
"The issuance of this patent further supports the unique and proprietary technology that differentiates our highly sensitive ctDNA platform technology," said
About ctDNA Target Selector™ Technology
The "switch-blocker" technology covered by this patent, as well as the earlier issued
In clinical validation studies,
About
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the
outcomes of cancer patients, the utility and effectiveness of our intellectual property protections, our ability to obtain additional patents in the future covering our proprietary liquid biopsy technology, our ability to generate sales in territories outside the
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-obtains-patent-in-australia-for-its-molecular-biomarker-technology-for-the-detection-of-cancer-associated-mutations-in-blood-tissue-and-other-biological-sources-300577482.html
SOURCE
News Provided by Acquire Media